Skip to content

Zymeworks ZYME Current ratio

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
1.3×+0.1×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
14.1×+3.9×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
15.1×-4.3×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
+0.6×

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Zymeworks’s reported figures.

Based on the most recent quarter.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's current ratio?
Zymeworks (ZYME) reported current ratio of 10.8× in Q1 2026.
How has Zymeworks's current ratio changed year-over-year?
Zymeworks's current ratio increased by 129.8% year-over-year, from 4.7× to 10.8×.
What is the long-term trend for Zymeworks's current ratio?
Over 4 years (2021 to 2025), Zymeworks's current ratio has grown at a 10.0% compound annual growth rate (CAGR), from 4× to 5.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.